StoryCommercial
Abeona: Zevaskyn revenue rises 31% to $11.4M in Q2 2026; 12 patients treated since launch
Abeona TherapeuticsZevaskyn (pz-cel)
Abeona reported $11.4M of Zevaskyn revenue in Q2 2026, up from $8.7M in Q1, with five patients treated in the quarter and 12 since launch. New treatment centres at Columbia, CHOP and Cincinnati Children's came online. Manufacturing remains the constraint: one Q2 batch produced too few sheets, and two treatments since launch could not be billed.
- Q2: 5 patients treated, 4 recognised as revenue; 3 more treated in Q3 to date.
- Medicare NTAP add-on payment effective 1 Oct 2026.
- Cash and investments $146.8M at 30 Jun 2026; Q2 net loss $20.2M.